Pharvaris’ Promising Oral Treatment Solutions For Treating Swollen Blood Vessels – Analyst Sees 35% Upside

Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ:PHVS), noting that the company stands out as one of the players with their strategy to develop and advance oral therapeutic options in both the acute and prophylactic settings for hereditary angioedema (HAE).

Analyst Laura Chico initiates with an Outperform rating, with a price target of $27 target.